uMedical
Medicines
Substances
Companies
Statistics
Menu
All medicines
Tepezza
Authorised
Human
Details
EMA number
EMEA/H/C/006396
ATC code
L04AG13
Authorisation
19 June 2025
Revision
1
EMA page
Therapeutic indication
Treatment of moderate to severe thyroid eye disease (TED).
MeSH:
Graves Ophthalmopathy
Group:
Immunosuppressants;Monoclonal antibodies
Special characteristics
Additional monitoring
Active substances
teprotumumab
Marketing Authorisation Holder
Amgen Europe B.V.
MAH
Timeline
Filter by authority:
EMA
Tepezza authorised
19 Jun 2025
authorised
regulatory
Tepezza | uMedical